Literature DB >> 10649245

Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma.

H Okuda1, T Nakanishi, K Takatsu, A Saito, N Hayashi, K Takasaki, K Takenami, M Yamamoto, M Nakano.   

Abstract

BACKGROUND: Des-gamma-carboxy prothrombin (DCP) is an established marker for hepatocellular carcinoma (HCC), but the conventional enzyme immunoassay (EIA) kit lacks adequate sensitivity. Thus, a revised EIA kit with increased sensitivity has been developed. In this kit, the sensitivity has increased while high specificity to HCC has been maintained. The authors have already reported the clinical usefulness of this revised EIA kit. In this study, they examined the serum levels of DCP measured by this revised EIA kit in relation to the clinicopathologic features of solitary HCC.
METHODS: Fifty-six patients with solitary HCC who underwent hepatectomy were studied. The relation between the greatest dimension and the histologic differentiation of HCC was investigated in these 56 patients, as were the serum levels of DCP measured by the revised EIA kit (Sensitive DCP), alpha-fetoprotein (AFP), and DCP measured by the conventional EIA kit (DCP). The cutoff value for Sensitive DCP was set at 40 mAU/mL, and the values for AFP and DCP were 20 ng/mL and 100 mAU/mL (0.1 AU/mL), respectively.
RESULTS: The positivity rates for Sensitive DCP, AFP, and DCP (n = 56) were 53.6%, 53.6%, and 35.7%, respectively, and the rate was 73.2% when Sensitive DCP was used in combination with AFP (Sensitive DCP + AFP). The positivity rates for these markers were as follows: 1) When the greatest dimension of HCC was more than 3 cm (n = 16) and less than 2 cm (n = 23), the rates were 81.3% and 30.4% for Sensitive DCP, 68. 8% and 39.1% for AFP, 56.3% and 13.0% for DCP, and 93.8% and 56.5% for Sensitive DCP + AFP. 2) When HCC was moderately to poorly differentiated (n = 41) and well differentiated (n = 15), the rates were 68.3% and 13.3% for Sensitive DCP, 61.0% and 33.3% for AFP, 48. 8% and 0% for DCP, and 85.4% and 40% for Sensitive DCP + AFP. 3) When HCC was either more than 3 cm or moderately to poorly differentiated (n = 42) and either less than 2 cm or well differentiated (n = 27), the rates were 69.0% and 29.6% for Sensitive DCP, 61.9% and 37.0% for AFP, 47.6% and 11.1% for DCP, and 85.7% and 51.9% for Sensitive DCP + AFP.
CONCLUSIONS: DCP measured by the revised EIA kit with increased sensitivity has a stronger correlation than AFP with size and histologic differentiation of HCC. This Sensitive DCP is a very useful marker for HCC and should be used in combination with AFP. Copyright 2000 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10649245

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  29 in total

1.  Impact of the preoperative des-gamma-carboxy prothrombin level on prognosis after hepatectomy for hepatocellular carcinoma meeting the Milan criteria.

Authors:  Takanori Sakaguchi; Shohachi Suzuki; Yoshifumi Morita; Kousuke Oishi; Atsushi Suzuki; Kazuhiko Fukumoto; Keisuke Inaba; Satoshi Nakamura; Hiroyuki Konno
Journal:  Surg Today       Date:  2010-06-26       Impact factor: 2.549

2.  Fucosylated fraction of alpha-fetoprotein as a predictor of prognosis in patients with hepatocellular carcinoma after curative treatment.

Authors:  Yasushi Tamura; Masato Igarashi; Takeshi Suda; Toshifumi Wakai; Yoshio Shirai; Takeji Umemura; Eiji Tanaka; Satoru Kakizaki; Hitoshi Takagi; Yoichi Hiasa; Morikazu Onji; Yutaka Aoyagi
Journal:  Dig Dis Sci       Date:  2010-07       Impact factor: 3.199

3.  Non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of outcomes for early-stage HCC.

Authors:  Hidenori Toyoda; Takashi Kumada; Toshifumi Tada; Yasuhiro Sone; Atsuyuki Maeda; Yuji Kaneoka
Journal:  Hepatol Int       Date:  2014-07-23       Impact factor: 6.047

4.  Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.

Authors:  Seung In Seo; Hyoung Su Kim; Won Jin Kim; Woon Geon Shin; Doo Jin Kim; Kyung Ho Kim; Myoung Kuk Jang; Jin Heon Lee; Joo Seop Kim; Hak Yang Kim; Dong Joon Kim; Myung Seok Lee; Choong Kee Park
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

5.  Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C.

Authors:  Katsutoshi Tokushige; Etsuko Hashimoto; Satoru Yatsuji; Maki Tobari; Makiko Taniai; Nobuyuki Torii; Keiko Shiratori
Journal:  J Gastroenterol       Date:  2010-04-08       Impact factor: 7.527

Review 6.  Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC.

Authors:  Hidenori Toyoda; Takashi Kumada; Toshifumi Tada; Yasuhiro Sone; Yuji Kaneoka; Atsuyuki Maeda
Journal:  Liver Cancer       Date:  2015-03       Impact factor: 11.740

7.  The complement component C3a fragment is a potential biomarker for hepatitis C virus-related hepatocellular carcinoma.

Authors:  Shuji Kanmura; Hirofumi Uto; Yuko Sato; Koutarou Kumagai; Fumisato Sasaki; Akihiro Moriuchi; Makoto Oketani; Akio Ido; Kenji Nagata; Katsuhiro Hayashi; Sherri O Stuver; Hirohito Tsubouchi
Journal:  J Gastroenterol       Date:  2009-12-09       Impact factor: 7.527

8.  Prognostic index of cirrhotic patients with hepatic encephalopathy with and without hepatocellular carcinoma.

Authors:  Keiichiro Yoneyama; Yuka Nebashi; Yuji Kiuchi; Minoru Shibata; Keiji Mitamura
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

Review 9.  Serum tumor markers for detection of hepatocellular carcinoma.

Authors:  Lin Zhou; Jia Liu; Feng Luo
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

10.  Exon 2 deletion splice variant of gamma-glutamyl carboxylase causes des-gamma-carboxy prothrombin production in hepatocellular carcinoma cell lines.

Authors:  Naoki Ueda; Hidenori Shiraha; Tatsuya Fujikawa; Nobuyuki Takaoka; Yutaka Nakanishi; Mayumi Suzuki; Noriyuki Matsuo; Shigetomi Tanaka; Shin-Ichi Nishina; Masayuki Uemura; Akinobu Takaki; Yasushi Shiratori; Kazuhide Yamamoto
Journal:  Mol Oncol       Date:  2008-06-20       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.